• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Krensavage Asset Management Remains Opposed to Sun's Predatory Bid for Taro

    1/30/24 7:00:00 AM ET
    $TARO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TARO alert in real time by email

    NEW YORK, Jan. 30, 2024 /PRNewswire/ -- Krensavage Asset Management today sent the following message to a special committee evaluating Sun Pharmaceutical Industries Ltd.'s bid for Taro Pharmaceutical Industries Ltd.

    Krensavage Asset Management LLC

    610 Fifth Avenue

    Suite 301

    New York, NY 10020

    [email protected] 

    Taro Special Committee

    Linda Benshoshan

    [email protected]

    Dear Linda,

    As the largest minority shareholder1 of Taro Pharmaceutical Industries Ltd. (NYSE:TARO), Krensavage Asset Management LLC remains opposed to Sun Pharmaceutical Industries Ltd.'s inadequate bid to take Taro private.

    Since we expressed our dismay in an open letter July 19, Sun, a 78.5% Taro shareholder, hiked its bid 13% to $43 a share, valuing Taro at $1.6 billion. Sun on May 26 disclosed a $38 lowball bid for Taro.

    Sun's new offer amounts to a 9% discount to the value of Taro's tangible assets, primarily $35 a share of net cash. Including real estate and other hard assets, Taro's liquidation value likely approaches $47 a share2.

    Sun is valuing Taro at $310 million, net of cash, for a business that generated $2.4 billion of cash in the 10 years ended March 31, the close of Taro's most-recent fiscal year.

    We question if the special committee Taro appointed to consider Sun's bid is neglecting its responsibility by embracing a transaction that fails to recognize Taro's carcass value, much less its ability to generate cash. None of Taro's board members own shares of the company, according to a November 17 proxy. 

    Taro shares would sell for $77 a share—before a takeover premium— if they traded at 4.9 times gross profit, the average multiple of six peers.

    Taro Peer Values



    Company

    Market Capitalization1

    ( $ millions )

    Net Cash ($ millions) 

    Enterprise Value 

    ($ millions)

    Revenue

    Multiple2

    Gross Profit

    Multiple2

    Free Cash Flow Yield

    over Enterprise Value3

    Teva Pharmaceutical Industries Ltd

    11,520

    -17,725

    29,245

    1.9

    3.9

    2 %

    Perrigo CompanyPlc

    4,481

    -3,488

    7,969

    1.8

    4.8

    4 %

    Viatris Inc

    13,839

    -17,075

    30,914

    2.0

    4.6

    7 %

    Sandoz Group AG4

    14,261

    -4,592

    18,853

    2.0

    4.0

    3 %

    Amneal Pharmaceuticals Inc

    1,606

    -2,602

    4,209

    1.7

    4.5

    3 %

    Amphastar Pharmaceuticals Inc

    3,027

    -338

    3,365

    4.7

    7.8

    4 %

    Mean







    2.3

    4.9

    4 %















    Taro Pharmaceutical Industries Ltd

    1,616

    1,306

    310

    0.5

    1.0

    28 %

    1Share prices as of 1/17/23, except for Taro which uses $43 offer price

    2 Latest quarter annualized

     3Trailing 12 months

    4Sandoz Group AG financials are as of 6/30/23

    Taro in an October 26 earnings report disclosed $6.1 million of spending primarily for the special committee's work including the hiring of an investment bank that has deemed Sun's bid fair to Taro's shareholders.

    Taro's bankers have lowballed before. In August 2012, when Sun was pursuing Taro in a bid that failed, an investment bank Taro hired to value the company relied on management's projections it would generate net income of $835 million between 2012 and 20163. Taro in fact generated $2.1 billion of net income.

    With a market value of $40.2 billion4, Sun can pay more. Sun is offering, net of Taro's cash, $67 million for the roughly 8.1 million Taro shares it doesn't own5. In December 2019, Taro paid $91 a share to repurchase its stock in a tender offer – more than twice Sun's current bid.

    Sun requires approval of the majority of Taro's minority shareholders. Unless Sun acknowledges Taro's value, we continue to decline to support the transaction.

    Michael P. Krensavage

    Managing member

    Krensavage Asset Management LLC

    Notes:

    1Krensavage Asset Management's 640,735 shares of Taro on September 30 make it Taro's No. 2 shareholder, according to Bloomberg.

    2Tangible assets reflect $1.8 billion of shareholders' equity less $17 million of goodwill. Weighted-average shares outstanding totaled 37.6 million in the quarter ended December 31.

    3Presentation to special committee August 12, 2012:

    sec.gov/Archives/edgar/data/906338/000094787112000742/ss157108_ex99c2.htm

    4Bloomberg lists Sun's closing market capitalization on January 29 as $40.2 billion.

    5Taro had 37,584,891 weighted-average shares outstanding in the quarter ended December 31. Sun controlled 29,497,813 shares of Taro according to Sun's Jan. 17 13D/A.

    Contact:

    David W. Walbert

    Senior Analyst

    Krensavage Asset Management LLC

    Office: (212) 706-0589

    [email protected]

    Cision View original content:https://www.prnewswire.com/news-releases/krensavage-asset-management-remains-opposed-to-suns-predatory-bid-for-taro-302047770.html

    SOURCE Krensavage Asset Management LLC

    Get the next $TARO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TARO

    DatePrice TargetRatingAnalyst
    1/18/2024$43.00Buy → Neutral
    H.C. Wainwright
    1/31/2022$75.00 → $73.00Buy
    HC Wainwright & Co.
    1/18/2022$82.00 → $75.00Buy
    HC Wainwright & Co.
    7/28/2021$80.00 → $82.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $TARO
    Leadership Updates

    Live Leadership Updates

    See more
    • Taro Appoints New Chief Financial Officer

      Taro Pharmaceutical Industries Ltd. (NYSE:TARO) ("Taro") today announced the appointment of William J. Coote as Vice President, Chief Financial Officer and Chief Accounting Officer, effective today. Mr. Coote has over 25 years of significant financial executive experience; most recently serving as Taro's AVP, Treasurer and Business Finance since 2008. Prior to joining Taro, Mr. Coote has held progressively responsible positions with a variety of global companies such as Bowne & Co., Prudential Realty, Merrill Lynch, and Ernst & Young. Throughout his career, he has been accountable for areas such as: Accounting, Treasury, Budgeting, Financial Planning and Analysis, Acquisitions, Investor R

      12/1/21 5:05:00 PM ET
      $TARO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Taro Announces Resignation of Chief Financial Officer

      Taro Pharmaceutical Industries Ltd. (NYSE:TARO) ("Taro" or the "Company") announced today that it has accepted the resignation of its Chief Financial Officer, Daphne Huang, effective August 6, 2021. Ms. Huang is leaving the Company in order to pursue other opportunities. Mr. Uday Baldota, Taro's CEO, stated, "On behalf of the Company, I want to thank Daphne for her valuable contributions including her efforts over the past year during the COVID-19 pandemic. We wish her the best in her future endeavors." The Company has initiated a search for a successor as Chief Financial Officer. About Taro Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, de

      7/14/21 5:54:00 PM ET
      $TARO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TARO
    Financials

    Live finance-specific insights

    See more
    • Taro to Release Third Quarter Results on January 25, 2024

      Taro Pharmaceutical Industries Ltd. (NYSE:TARO) announced today that it plans to release its financial results for the third quarter ended December 31, 2023, after the close of market on Thursday, January 25, 2024. The release will be accessible on Taro's website at www.taro.com. About Taro Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the highest quality healthcare products. For further information on Taro Pharmaceutical Industries Ltd., please visit the Company's website at www.taro.com. View source version on businesswir

      1/19/24 4:15:00 PM ET
      $TARO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Taro to Release Second Quarter Results on October 26, 2023

      Taro Pharmaceutical Industries Ltd. (NYSE:TARO) announced today that it plans to release its financial results for the second quarter ended September 30, 2023, after the close of market on Thursday, October 26, 2023. The release will be accessible on Taro's website at www.taro.com. About Taro Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the highest quality healthcare products. For further information on Taro Pharmaceutical Industries Ltd., please visit the Company's website at www.taro.com. View source version on businessw

      10/19/23 4:30:00 PM ET
      $TARO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Taro to Release First Quarter Results on July 26, 2023

      Taro Pharmaceutical Industries Ltd. (NYSE:TARO) announced today that it plans to release its financial results for the first quarter ended June 30, 2023, after the close of market on Wednesday, July 26, 2023. The release will be accessible on Taro's website at www.taro.com. About Taro Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the highest quality healthcare products. For further information on Taro Pharmaceutical Industries Ltd., please visit the Company's website at www.taro.com. View source version on businesswire.com: h

      7/19/23 4:00:00 PM ET
      $TARO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TARO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Sun Pharma Completes Taro Merger

      Combined entity is better positioned to compete in increasingly competitive generics industry MUMBAI, India and PRINCETON, N.J., June 24, 2024 /PRNewswire/ -- Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715 (together with its subsidiaries and/or associated companies, "Sun Pharma")) today announced the successful completion of the merger of Taro Pharmaceutical Industries Ltd. (NYSE:TARO) ("Taro") with its subsidiary.  As part of this merger, Sun Pharma acquired all outstanding ordinary shares of Taro other than the shares already held by Sun Pharma or its affiliates. As a result of the merger, Taro is now a private company and wholly-own

      6/24/24 7:47:00 AM ET
      $TARO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Taro Shareholders Approve Merger with Sun Pharma

      MUMBAI, India and NEW YORK, May 23, 2024 /PRNewswire/ -- Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associates referred as "Sun Pharma") and Taro Pharmaceutical Industries Ltd. (NYSE:TARO) ("Taro" or the "Company") today announced that the merger agreement between Taro and Sun Pharma was approved by the affirmative vote of Taro shareholders (including a vote of the majority of shares held by Taro shareholders unaffiliated with Sun Pharma) at an Extraordinary General Meeting and an Ordinary Class Meeting on May 22, 2024. The details of the merger agreement were announced on January 17, 2024.

      5/23/24 7:50:00 AM ET
      $TARO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Taro Provides Results for Year Ended March 31, 2024

      Taro Pharmaceutical Industries Ltd. (NYSE:TARO) ("Taro" or the "Company") today provided unaudited financial results for the quarter and year ended March 31, 2024. Quarter ended March 31, 2024 Highlights ─ compared to March 31, 2023 Net sales of $164.9 million increased $18.4 million, or 12.5%, principally due to new launches and gross-to-net ("GTN") adjustments. Excluding the impact of GTN adjustments, sales growth was high single digits. Gross profit of $87.4 million (53.0% of net sales) compared to $75.7 million (51.6% of net sales). Research and development (R&D) expenses of $20.5 million increased $4.2 million. Selling, marketing, general and administrative expenses (SG&A

      5/20/24 5:00:00 PM ET
      $TARO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TARO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Taro Pharmaceutical Industries Ltd.

      SC 13D/A - TARO PHARMACEUTICAL INDUSTRIES LTD (0000906338) (Subject)

      6/24/24 7:27:26 AM ET
      $TARO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Taro Pharmaceutical Industries Ltd. (Amendment)

      SC 13D/A - TARO PHARMACEUTICAL INDUSTRIES LTD (0000906338) (Subject)

      1/17/24 4:35:31 PM ET
      $TARO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Taro Pharmaceutical Industries Ltd. (Amendment)

      SC 13D/A - TARO PHARMACEUTICAL INDUSTRIES LTD (0000906338) (Subject)

      12/11/23 4:30:41 PM ET
      $TARO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TARO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Taro Pharm downgraded by H.C. Wainwright with a new price target

      H.C. Wainwright downgraded Taro Pharm from Buy to Neutral and set a new price target of $43.00

      1/18/24 7:15:24 AM ET
      $TARO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on Taro Pharmaceutical Indus with a new price target

      HC Wainwright & Co. reiterated coverage of Taro Pharmaceutical Indus with a rating of Buy and set a new price target of $73.00 from $75.00 previously

      1/31/22 6:44:12 AM ET
      $TARO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on Taro Pharmaceutical Indus with a new price target

      HC Wainwright & Co. reiterated coverage of Taro Pharmaceutical Indus with a rating of Buy and set a new price target of $75.00 from $82.00 previously

      1/18/22 9:38:57 AM ET
      $TARO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TARO
    SEC Filings

    See more
    • SEC Form 15F-12B filed by Taro Pharmaceutical Industries Ltd.

      15F-12B - TARO PHARMACEUTICAL INDUSTRIES LTD (0000906338) (Filer)

      7/5/24 11:25:50 AM ET
      $TARO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 25-NSE filed by Taro Pharmaceutical Industries Ltd.

      25-NSE - TARO PHARMACEUTICAL INDUSTRIES LTD (0000906338) (Subject)

      6/24/24 10:01:21 AM ET
      $TARO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13E3/A filed by Taro Pharmaceutical Industries Ltd.

      SC 13E3/A - TARO PHARMACEUTICAL INDUSTRIES LTD (0000906338) (Subject)

      6/24/24 7:09:07 AM ET
      $TARO
      Biotechnology: Pharmaceutical Preparations
      Health Care